Prostate cancer detection and diagnosis: The role of MR and its comparison with other diagnostic modalities - a radiologist's perspective

NMR in Biomedicine

Volumn 27, Issue 1, 2014, Pages 3-15

  Penzkofer, Tobias ^a,b   Tempany Afdhal, Clare M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Diffusion weighted imaging; Dynamic contrast enhancement (DCE) imaging; MR elastography (MRE); Post acquisition processing; Prostate cancer; Prostate MRI

Indexed keywords

DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCEMENT; MR ELASTOGRAPHY; POST-ACQUISITION PROCESSING; PROSTATE CANCERS;

BIOPSY; DISEASES; MEDICAL IMAGING; RADIOTHERAPY; ULTRASONIC APPLICATIONS; ULTRASONICS; UROLOGY;

MAGNETIC RESONANCE IMAGING;

ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ELASTOGRAPHY; GLEASON SCORE; HUMAN; IMAGING SOFTWARE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; RADIOLOGIST; THREE DIMENSIONAL IMAGING; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING;

DIFFUSION-WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCEMENT (DCE) IMAGING; MR ELASTOGRAPHY (MRE); POST-ACQUISITION PROCESSING; PROSTATE CANCER; PROSTATE MRI;

BIOPSY; ELASTICITY IMAGING TECHNIQUES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84890886994     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3002     Document Type: Article

References (108)

1. National Institutes of Health. Prostate Cancer. National Institutes of Health: Bethesda, MD; 2012.
2. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL. Early detection of prostate cancer: AUA Guideline. J. Urol. 2013; 190(2): 419-426.
3. US Preventive Screening Task Force. Screening for Prostate Cancer, http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatefinalrs.htm.
4. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012; 157(2): 120-134.
5. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J. Urol. 2013; 189(1 Suppl): S12-S18.
6. Sonn GA, Natarajan S, Margolis DJA, MacAiran M, Lieu P, Huang J, Dorey FJ, Marks LS. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J. Urol. 2012; 189(1): 86-91.
7. Isariyawongse BK, Sun L, Banez LL, Robertson C, Polascik TJ, Maloney K, Donatucci C, Albala D, Mouraviev V, Madden JF, Moul JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology 2008; 72(4): 882-886.
8. Yakar D, Debats OA, Bomers JG, Schouten MG, Vos PC, van Lin E, Futterer JJ, Barentsz JO. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J. Magn. Reson. Imaging 2012; 35(1): 20-31.
9. Turkbey B, Choyke PL. Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr. Opin. Urol. 2012; 22(4): 310-315.
10. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 2008; 179(5): 1804-1809; discussion 1809-1810.
11. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69(3): 532-535.
12. Hegde JV, Mulkern RV, Panych LP, Fennessy FM, Fedorov A, Maier SE, Tempany CM. Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J. Magn. Reson. Imaging 2013; 37(5): 1035-1054.
13. Kobus T, Vos PC, Hambrock T, De Rooij M, Hulsbergen-Van de Kaa CA, Barentsz JO, Heerschap A, Scheenen TW. Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3T. Radiology 2012; 265(2): 457-467.
14. Sciarra A, Panebianco V, Salciccia S, Gentilucci A, Alfarone A, Dimare L, Lisi D, Catturino S, Di Pierro G, Von Heland M, Ciccariello M, Passariello R, Gentile V. Value of magnetic resonance spectroscopy (MRS) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci. Urol. Oncol. 2011; 29(6): 634-640.
15. Scheenen TW, Futterer J, Weiland E, van Hecke P, Lemort M, Zechmann C, Schlemmer HP, Broome D, Villeirs G, Lu J, Barentsz J, Roell S, Heerschap A. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest. Radiol. 2011; 46(1): 25-33.
16. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur. Urol. 2011; 59(4): 477-494.
17. van de Ven WJ, Hulsbergen-van de Kaa CA, Hambrock T, Barentsz JO, Huisman HJ. Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies. Eur. Radiol. 2013; 23(5): 1401-1407.
18. Eberhardt SC, Carter S, Casalino DD, Merrick G, Frank SJ, Gottschalk AR, Leyendecker JR, Nguyen PL, Oto A, Porter C, Remer EM, Rosenthal SA. ACR Appropriateness Criteria prostate cancer - pretreatment detection, staging, and surveillance. J. Am. Coll. Radiol. 2013; 10(2): 83-92.
19. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TW. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3T with an endorectal coil. Eur. Urol. 2011; 60(5): 1074-1080.
20. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 2007; 245(2): 507-516.
21. Heijmink SW, Futterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, Hulsbergen-Van de Kaa CA, Knipscheer BC, Kiemeney LA, Witjes JA, Barentsz JO. Prostate cancer: body-array versus endorectal coil MR imaging at 3T - comparison of image quality, localization, and staging performance. Radiology 2007; 244(1): 184-195.
22. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS, Grubb RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, on behalf of the SC. Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. Eur. Urol. 2013; ePub ahead of print.
23. Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology 2012; 263(3): 751-757.
24. Purysko AS, Herts BR. Prostate MRI: the hemorrhage exclusion sign. J. Urol. 2012; 188(5): 1946-1947.
25. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236(3): 903-910.
26. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini GC, Albert PS, Merino MJ, Choyke PL. Prostate cancer: value of multiparametric MR imaging at 3T for detection - histopathologic correlation. Radiology 2010; 255(1): 89-99.
27. Rosen Y, Bloch BN, Lenkinski RE, Greenman RL, Marquis RP, Rofsky NM. 3T MR of the prostate: reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension. Magn. Reson. Med. 2007; 57(5): 898-904.
28. Noworolski SM, Crane JC, Vigneron DB, Kurhanewicz J. A clinical comparison of rigid and inflatable endorectal-coil probes for MRI and 3D MR spectroscopic imaging (MRSI) of the prostate. J. Magn. Reson. Imaging 2008; 27(5): 1077-1082.
29. 2). J. Magn. Reson. Imaging 2012; 36(1): 198-205.
30. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, Scheenen T, Barentsz JO. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259(2): 453-461.
31. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Futterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score
32. Rosenkrantz AB, Sigmund EE, Johnson G, Babb JS, Mussi TC, Melamed J, Taneja SS, Lee VS, Jensen JH. Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. Radiology 2012; 264(1): 126-135.
33. Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL. Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. Eur. Radiol. 2012; 22(2): 468-475.
34. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211(1): 101-110.
35. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 1999; 10(3): 223-232.
36. Fennessy FM, Fedorov A, Gupta SN, Schmidt EJ, Tempany CM, Mulkern RV. Practical considerations in T1 mapping of prostate for dynamic contrast enhancement pharmacokinetic analyses. Magn. Reson. Imaging 2012; 30(9): 1224-1233.
37. Tokuda J, Tuncali K, Iordachita I, Song SE, Fedorov A, Oguro S, Lasso A, Fennessy FM, Tempany CM, Hata N. In-bore setup and software for 3T MRI-guided transperineal prostate biopsy. Phys. Med. Biol. 2012; 57(18): 5823-5840.
38. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Futterer JJ, Barentsz JO. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J. Urol. 2010; 183(2): 520-527.
39. Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Futterer JJ, Barentsz JO. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur. Urol. 2012; 62(5): 902-909.
40. Overduin CG, Futterer JJ, Barentsz JO. MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Curr. Urol. Rep. 2013; 14(3): 209-213.
41. Aydin H, Kizilgoz V, Tatar IG, Damar C, Ugan AR, Paker I, Hekimoglu B. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. J. Comput. Assist. Tomogr. 2012; 36(1): 30-45.
42. Kimm SY, Tarin TV, Lee JH, Hu B, Jensen K, Nishimura D, Brooks JD. Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology. J. Magn. Reson. Imaging, 2012; 36(1): 206-212.
43. Mazaheri Y, Bokacheva L, Kroon DJ, Akin O, Hricak H, Chamudot D, Fine S, Koutcher JA. Semi-automatic deformable registration of prostate MR images to pathological slices. J. Magn. Reson. Imaging 2010; 32(5): 1149-1157.
44. Trivedi H, Turkbey B, Rastinehad AR, Benjamin CJ, Bernardo M, Pohida T, Shah V, Merino MJ, Wood BJ, Linehan WM, Venkatesan AM, Choyke PL, Pinto PA. Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology 2012; 79(1): 233-239.
45. Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz C, Udo K, Eastham J, Hricak H. Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011; 259(3): 775-784.
46. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Futterer J, Bouwense S, van Oort I, Schroder F, Huisman H, Barentsz J. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur. Urol. 2012; 61(1): 177-184.
47. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012; 13(6): 622-632.
48. Gangi A, Tsoumakidou G, Abdelli O, Buy X, de Mathelin M, Jacqmin D, Lang H. Percutaneous MR-guided cryoablation of prostate cancer: initial experience. Eur. Radiol. 2012; 22(8): 1829-1835.
49. Napoli A, Anzidei M, De Nunzio C, Cartocci G, Panebianco V, De Dominicis C, Catalano C, Petrucci F, Leonardo C. Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. Eur. Urol. 2013; 63(2): 395-398.
50. D'Amico AV, Cormack RA, Tempany CM. MRI-guided diagnosis and treatment of prostate cancer. N. Engl. J. Med. 2001; 344(10): 776-777.
51. Hata N, Jinzaki M, Kacher D, Cormak R, Gering D, Nabavi A, Silverman SG, D'Amico AV, Kikinis R, Jolesz FA, Tempany CM. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology 2001; 220(1): 263-268.
52. Cormack RA, D'Amico AV, Hata N, Silverman S, Weinstein M, Tempany CM. Feasibility of transperineal prostate biopsy under interventional magnetic resonance guidance. Urology 2000; 56(4): 663-664.
53. D'Amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology 2003; 62(6): 1063-1067.
54. Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J. Urol. 2012; 188(4): 1151-1156.
55. Fedorov A, Tuncali K, Fennessy FM, Tokuda J, Hata N, Wells WM, Kikinis R, Tempany CM. Image registration for targeted MRI-guided transperineal prostate biopsy. J. Magn. Reson. Imaging 2012; 36(4): 987-992.
56. Pursley J, Risholm P, Fedorov A, Tuncali K, Fennessy FM, Wells WM, Tempany CM, Cormack RA. A Bayesian nonrigid registration method to enhance intraoperative target definition in image-guided prostate procedures through uncertainty characterization. Med. Phys. 2012; 39(11): 6858-6867.
57. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, Buatti J, Aylward S, Miller JV, Pieper S, Kikinis R. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn. Reson. Imaging 2012; 30(9): 1323-1341.
58. Penzkofer T, Tuncali K, Fedorov A, Tokuda J, Song SE, Hata N, Gupta GN, Mulkern RV, Fennessy FM, Tempany CM. Multiparametric MRI and pharmakokinetic maps for prostate cancer detection: value in a multireader decision transperineal biopsy study. Proceedings of the 21st Annual Meeting ISMRM, Salt Lake City, UT, USA, 2013; 1770.
59. Watanabe H, Igari D, Tanahasi Y, Harada K, Saito M. Development and application of new equipment for transrectal ultrasonography. J. Clin. Ultrasound 1974; 2(2): 91-98.
60. Heijmink SW, Futterer JJ, Strum SS, Oyen WJ, Frauscher F, Witjes JA, Barentsz JO. State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer. Acta Oncol. 2011; 50(Suppl 1): 25-38.
61. Meirelles LR, Billis A, Cotta AC, Nakamura RT, Caserta NM, Prando A. Prostatic atrophy: evidence for a possible role of local ischemia in its pathogenesis. Int. Urol. Nephrol. 2002; 34(3): 345-350.
62. Lee F, Gray JM, McLeary RD, Lee F Jr, McHugh TA, Solomon MH, Kumasaka GH, Straub WH, Borlaza GS, Murphy GP. Prostatic evaluation by transrectal sonography: criteria for diagnosis of early carcinoma. Radiology 1986; 158(1): 91-95.
63. Ellis WJ, Brawer MK. The significance of isoechoic prostatic carcinoma. J. Urol. 1994; 152(6 Pt 2): 2304-2307.
64. Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger M. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012; 110(7): 942-948.
65. Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schroder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int. J. Cancer 1999; 84(4): 437-441.
66. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat. Rev. Urol. 2009; 6(4): 191-203.
67. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur. Urol. 2007; 52(5): 1309-1322.
68. Ganzer R, Brandtner A, Wieland WF, Fritsche HM. Prospective blinded comparison of real-time sonoelastography targeted versus randomised biopsy of the prostate in the primary and re-biopsy setting. World J. Urol. 2012; 30(2): 219-223.
69. Salomon G, Kollerman J, Thederan I, Chun FK, Budaus L, Schlomm T, Isbarn H, Heinzer H, Huland H, Graefen M. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur. Urol. 2008; 54(6): 1354-1362.
70. Pallwein L, Mitterberger M, Struve P, Horninger W, Aigner F, Bartsch G, Gradl J, Schurich M, Pedross F, Frauscher F. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur. Radiol. 2007; 17(9): 2278-2285.
71. Brock M, von Bodman C, Palisaar RJ, Loppenberg B, Sommerer F, Deix T, Noldus J, Eggert T. The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients. J. Urol. 2012; 187(6): 2039-2043.
72. Arani A, Plewes D, Chopra R. Transurethral prostate magnetic resonance elastography: prospective imaging requirements. Magn. Reson. Med. 2011; 65(2): 340-349.
73. Arani A, Plewes D, Krieger A, Chopra R. The feasibility of endorectal MR elastography for prostate cancer localization. Magn. Reson. Med. 2011; 66(6): 1649-1657.
74. Sahebjavaher RS, Baghani A, Honarvar M, Sinkus R, Salcudean SE. Transperineal prostate MR elastography: initial in vivo results. Magn. Reson. Med. 2013; 69(2): 411-420.
75. Chopra R, Arani A, Huang Y, Musquera M, Wachsmuth J, Bronskill M, Plewes D. In vivo MR elastography of the prostate gland using a transurethral actuator. Magn. Reson. Med. 2009; 62(3): 665-671.
76. Kemper J, Sinkus R, Lorenzen J, Nolte-Ernsting C, Stork A, Adam G. MR elastography of the prostate: initial in-vivo application. Fortschr. Geb. Rontgenstr. Nuklearmed. 2004; 176(8): 1094-1099.
77. Li S, Chen M, Wang W, Zhao W, Wang J, Zhao X, Zhou C. A feasibility study of MR elastography in the diagnosis of prostate cancer at 3.0T. Acta Radiol. 2011; 52(3): 354-358.
78. Thormer G, Reiss-Zimmermann M, Otto J, Hoffmann KT, Moche M, Garnov N, Kahn T, Busse H. Novel technique for MR elastography of the prostate using a modified standard endorectal coil as actuator. J. Magn. Reson. Imaging 2013; 37(6): 1480-1485.
79. Zhai L, Madden J, Foo WC, Mouraviev V, Polascik TJ, Palmeri ML, Nightingale KR. Characterizing stiffness of human prostates using acoustic radiation force. Ultrason. Imaging 2010; 32(4): 201-213.
80. Barr RG, Memo R, Schaub CR. Shear wave ultrasound elastography of the prostate: initial results. Ultrasound Q. 2012; 28(1): 13-20.
81. Brock M, Eggert T, Palisaar RJ, Roghmann F, Braun K, Loppenberg B, Sommerer F, Noldus J, von Bodman C. Multiparametric ultrasound of the prostate: adding contrast enhanced ultrasound to real-time elastography to detect histopathologically confirmed cancer. J. Urol. 2013; 189(1): 93-98.
82. Smeenge M, de la Rosette JJ, Wijkstra H. Current status of transrectal ultrasound techniques in prostate cancer. Curr. Opin. Urol. 2012; 22(4): 297-302.
83. Zhao HX, Zhu Q, Wang ZC. Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy results. Br. J. Radiol. 2012; 85(1014): 714-719.
84. Nelson ED, Slotoroff CB, Gomella LG, Halpern EJ. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology 2007; 70(6): 1136-1140.
85. Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008; 101(3): 293-298.
86. Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, Treurnicht K, Jarmulowicz M, Bleiberg H, Govindaraju S, Emberton M. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008; 102(11): 1560-1565.
87. Simmons LA, Autier P, Zat'ura F, Braeckman J, Peltier A, Romic I, Stenzl A, Treurnicht K, Walker T, Nir D, Moore CM, Emberton M. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning™. BJU Int. 2012; 110(1): 28-35.
88. Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T. Accuracy of HistoScanning for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int. 2013; 111(1): 60-66.
89. Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Current Opin. Urol. 2013; 23(1): 43-50.
90. Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, Taneja SS, Emberton M. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur. Urol. 2013; 63(1): 125-140.
91. Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, Choyke PL, Wood BJ. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int. 2008; 101(7): 841-845.
92. Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, Turkbey B, Gupta GN, Kruecker J, Linehan WM, Choyke PL, Wood BJ, Pinto PA. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J. Urol. 2012; 188(6): 2152-2157.
93. Miyagawa T, Ishikawa S, Kimura T, Suetomi T, Tsutsumi M, Irie T, Kondoh M, Mitake T. Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int. J. Urol. 2010; 17(10): 855-860.
94. Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, Xu S, Yan P, Kadoury S, Chua C, Locklin JK, Turkbey B, Shih JH, Gates SP, Buckner C, Bratslavsky G, Linehan WM, Glossop ND, Choyke PL, Wood BJ. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J. Urol. 2011; 186(4): 1281-1285.
95. Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, Aron M, Gill IS. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J. Urol. 2012; 187(3): 1080-1086.
96. Fiard G, Hohn N, Descotes JL, Rambeaud JJ, Troccaz J, Long JA. Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance/transrectal ultrasound image fusion. Urology 2013; 81(6): 1372-1378.
97. Kuru TH, Tulea C, Simpfendörfer T, Popeneciu V, Roethke M, Hadaschik BA, Hohenfellner M. MRI navigated stereotactic prostate biopsy: fusion of MRI and real-time transrectal ultrasound images for perineal prostate biopsies. Urologe 2012; 51(1): 50-56.
98. Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendorfer T, Huber J, Zogal P, Teber D, Pahernik S, Roethke M, Zamecnik P, Roth W, Sakas G, Schlemmer HP, Hohenfellner M. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J. Urol. 2011; 186(6): 2214-2220.
99. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, Huppertz A, Miller K, Strecker R, Hamm B. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259(1): 162-172.
100. Hambrock T, Futterer JJ, Huisman HJ, Hulsbergen-vandeKaa C, van Basten JP, van Oort I, Witjes JA, Barentsz JO. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest. Radiol. 2008; 43(10): 686-694.
101. Xu S, Kruecker J, Guion P, Glossop N, Neeman Z, Choyke P, Singh AK, Wood BJ. Closed-loop control in fused MR-TRUS image-guided prostate biopsy. Medical Image Computing and Computer-Assisted Intervention (MICCAI) International Conference on Medical Image Computing and Computer-Assisted Intervention 2007; 10(Pt 1): 128-135.
102. Xu S, Kruecker J, Turkbey B, Glossop N, Singh AK, Choyke P, Pinto P, Wood BJ. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput. Aid. Surg. 2008; 13(5): 255-264.
103. Heijmink SW, Scheenen TW, van Lin EN, Visser AG, Kiemeney LA, Witjes JA, Barentsz JO. Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. Int. J. Radiat. Oncol. Biol. Phys. 2009; 73(5): 1446-1453.
104. Hu Y, Ahmed HU, Taylor Z, Allen C, Emberton M, Hawkes D, Barratt D. MR to ultrasound registration for image-guided prostate interventions. Med. Image Anal. 2012; 16(3): 687-703.
105. Ives EP, Burke MA, Edmonds PR, Gomella LG, Halpern EJ. Quantitative computed tomography perfusion of prostate cancer: correlation with whole-mount pathology. Clin. Prostate Cancer 2005; 4(2): 109-112.
106. Cyran CC, von Einem JC, Paprottka PM, Schwarz B, Ingrisch M, Dietrich O, Hinkel R, Bruns CJ, Clevert DA, Eschbach R, Reiser MF, Wintersperger BJ, Nikolaou K. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. Invest. Radiol. 2012; 47(1): 49-57.
107. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011; 12(2): 181-191.
108. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J. Urol. 1996; 155(3): 994-998.